PAM
ALXN

Paradigm Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Paradigm Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,050
Closed -$377K – 323
2021
Q2 		$377K Sell
2,050
-200
-9% -$34.3K 0.1% 283
2021
Q1 		$344K Sell
2,250
-200
-8% -$30.9K 0.09% 287
2020
Q4 		$383K Buy
2,450
+700
+40% +$90K 0.11% 278
2020
Q3 		$200K Hold
1,750
– – 0.06% 322
2020
Q2 		$196K Buy
+1,750
New +$186K 0.06% 326
2019
Q2 		– Sell
-300
Closed -$40.6K – 436
2019
Q1 		$40.6K Sell
300
-150
-33% -$18.7K 0.01% 362
2018
Q4 		$43.8K Sell
450
-150
-25% -$17.7K 0.01% 357
2018
Q3 		$83.4K Buy
600
+50
+9% +$6.27K 0.02% 343
2018
Q2 		$68.3K Hold
550
– – 0.02% 340
2018
Q1 		$61.3K Hold
550
– – 0.02% 344
2017
Q4 		$65.8K Buy
550
+50
+10% +$6.09K 0.02% 343
2017
Q3 		$70.1K Hold
500
– – 0.02% 347
2017
Q2 		$60.8K Sell
500
-850
-63% -$98.9K 0.01% 495
2017
Q1 		$164K Buy
+1,350
New +$174K 0.03% 411
2015
Q1 		– Sell
-2,540
Closed -$470K – 861
2014
Q4 		$470K Hold
2,540
– – 0.06% 323
2014
Q3 		$421K Sell
2,540
-200
-7% -$32.8K 0.06% 335
2014
Q2 		$428K Hold
2,740
– – 0.06% 347
2014
Q1 		$417K Hold
2,740
– – 0.06% 349
2013
Q4 		$365K Sell
2,740
-1,550
-36% -$186K 0.06% 394
2013
Q3 		$498K Hold
4,290
– – 0.08% 267
2013
Q2 		$396K Buy
+4,290
New +$413K 0.07% 340

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Paradigm Asset Management's ALXN Position: Q3 2021 in Review

Paradigm Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,050 shares — an estimated $377K sold.

Paradigm Asset Management first reported a position in ALXN in Q2 2013 and held it in 21 quarters. The position peaked at $498K in Q3 2013. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Paradigm Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Paradigm Asset Management sold 2,050 Alexion Pharmaceuticals shares in Q3 2021, an estimated $377K.
  • Paradigm Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 21 quarters.
  • Paradigm Asset Management's Alexion Pharmaceuticals position peaked at $498K in Q3 2013.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Paradigm Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.